These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36880572)

  • 21. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.
    Feldman AG; Beaty BL; Ferrolino JA; Maron G; Weidner HK; Ali SA; Bitterfeld L; Boulware MA; Campbell KM; Carr E; Chapman S; Chang YC; Cunningham R; Dallas RH; Dantuluri KL; Domenick BN; Ebel NH; Elisofon S; Fawaz R; Foca M; Gans HA; Gopalareddy VV; Gu C; Gupta NA; Harmann K; Hollenbeck J; Huppler AR; Jaramillo C; Kasi N; Kerkar N; Lerret S; Lobritto SJ; Lopez MJ; Marini E; Mavis A; Mehra S; Moats L; Mohandas S; Munoz FM; Mysore KR; Onsan C; Ovchinsky N; Perkins K; Postma S; Pratscher L; Rand EB; Rowe RK; Schultz D; Sear K; Sell ML; Sharma T; Stoll J; Vang M; Villarin D; Weaver C; Wood P; Woodford-Berry O; Yanni G; Danziger-Isakov LA
    JAMA Netw Open; 2023 Oct; 6(10):e2337602. PubMed ID: 37824141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of maternal measles-rubella immunization on the 12-month-old infant's immune response to measles-mumps-rubella vaccine immunogenicity.
    Saffar MJ; Ajami A; Khalilian AR; Saffar H
    Eur J Clin Microbiol Infect Dis; 2009 Jul; 28(7):845-7. PubMed ID: 19229565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.
    Pittet LF; Verolet CM; McLin VA; Wildhaber BE; Rodriguez M; Cherpillod P; Kaiser L; Siegrist CA; Posfay-Barbe KM
    Am J Transplant; 2019 Mar; 19(3):844-854. PubMed ID: 30171797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
    Nakayama T; Eda M; Hirano M; Goto W
    Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: An observational study.
    Ogawa T; Inoue T; Kasahara K; Konishi M; Mikasa K
    PLoS One; 2020; 15(3):e0230329. PubMed ID: 32208432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
    Vizzotti C; Harris JB; Aquino A; Rancaño C; Biscayart C; Bonaventura R; Pontoriero A; Baumeister E; Freire MC; Magariños M; Duarte B; Grant G; Reef S; Laven J; Wannemuehler KA; Alvarez AMR; Staples JE
    BMC Infect Dis; 2023 Mar; 23(1):165. PubMed ID: 36932346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMR vaccination timing and long-term immunity among childhood cancer survivors.
    Speckhart SA
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30133. PubMed ID: 36602013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
    Klein NP; Abu-Elyazeed R; Povey M; Macias Parra M; Diez-Domingo J; Ahonen A; Korhonen T; Tinoco JC; Weiner L; Marshall GS; Silas PE; Sarpong KO; Ramsey KP; Fling JA; Speicher D; Campos M; Munjal I; Peltier C; Vesikari T; Baccarini C; Caplanusi A; Gillard P; Carryn S; Henry O
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):194-201. PubMed ID: 30849175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successes and challenges for preventing measles, mumps and rubella by vaccination.
    Bankamp B; Hickman C; Icenogle JP; Rota PA
    Curr Opin Virol; 2019 Feb; 34():110-116. PubMed ID: 30852425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.